Phase III Data Show That Novartis Meningococcal Vaccine Menveo Demonstrated Robust Immunogenicity in infants - Drugs.com MedNews
Links shared publicly online about this topic.
- 776total visits
Phase III Data Show That Novartis Meningococcal Vaccine Menveo Demonstrated Robust Immunogenicity in infants - Drugs.com MedNews
New pivotal phase III data show Menveo induced immune responses in a high percentage of infants against four important meningococcal disease-causing serogroups
View full resource at drugs.com
Tags: Immune, Vaccination, Drug, Children's Health, Vaccine, Novartis
Most Recently Shared on October 25, 2010 at 2:12 pm By:
Phase III Data Show That Novartis Meningococcal Vaccine Menveo Demonstrated Robust Immunogenicity in infants:... http://bit.ly/aDWiiO #drug
Advertisement
